Le Lézard
Classified in: Health, Science and technology

Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders

CALGARY, Alberta, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix", or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the "Meeting") in Calgary, Alberta. A total of 126,864,830 shares (approximately 71.50% of outstanding common shares) were represented in person or by proxy.

During business proceedings at the Meeting, shareholders elected six (6) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:

   Votes ForVotes WithheldPercent ForPercent Withheld
Donald J. McCaffrey119,460,894341,14399.720.28
Norma Biln119,660,378141,65999.880.12
Shawn Lu119,594,448207,58999.830.17
Kelly McNeill119,661,978140,05999.880.12
Dr. Eldon Smith119,681,648120,38999.900.10
Kenneth Zuerblis119,615,048186,98999.840.16

Resverlogix shareholders approved all resolutions, including an amendment to the Corporation's articles to potentially consolidate the issued and outstanding common shares, outlined in the Notice of Meeting and Management Information Circular dated July 27, 2018 (the "Information Circular"). The Information Circular is available on SEDAR at www.sedar.com, and on the Resverlogix website at www.resverlogix.com.

A webcast archive of the executive presentation portion of the Meeting is available here.

The Corporation also announces that it expects to file its unaudited interim Consolidated Financial Statements and Management's Discussion & Analysis for the quarter ended July 31, 2018 with Canadian securities regulatory authorities on September 14, 2018. These materials will be available on the Resverlogix website, and on SEDAR, shortly after being filed.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX

These press releases may also interest you

at 11:03
A September 20 news release regarding the Alberta Medical Association's 2018 Medal for Distinguished Service awards contained a factual error. Due to a missed step in our review process, the biographical information regarding recipient Dr. John...

at 11:01
Brian Evans, singer and nominee for Hawaii's 2nd congressional district, and the Physician-Patient Alliance for Health & Safety (PPAHS) announce plans to evaluate hospitals on their sleep apnea preparedness. Helen Marie Bousquet tragically passed...

at 11:00
WACO, Texas, Sept. 26, 2018 /PRNewswire-PRWeb/ -- AxisCare Home Care Software has partnered with CareBuilders at Home to offer its state-of-the-art home care management software to their numerous home care agencies across the country. The software...

at 11:00
Comau, the global leader in advanced industrial automation solutions, launches MATE, its first innovative wearable exoskeleton. MATE has been designed to improve work quality in an efficient and highly ergonomic manner by providing consistent and...

at 11:00
Some of top players in care management solutions market are EXL Service Holdings, Inc. (US), Casenet, LLC (US), Medecision Inc. (US), ZeOmega Inc. (US), Cognizant Technology Solutions (US), Cerner Corporation (US), Allscripts Healthcare Solutions,...

at 11:00
CHARLOTTE, N.C., Sept. 26, 2018 /PRNewswire-PRWeb/ -- Jeff Stovall has been selected as the first Chief Operating Officer for PMMC, the Charlotte-based healthcare software company announced today. PMMC is a leading healthcare revenue cycle software...

News published on 12 september 2018 at 18:33 and distributed by: